Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) EVP Bob D. Brown sold 10,000 shares of the business’s stock in a transaction on Monday, June 7th. The stock was sold at an average price of $33.00, for a total transaction of $330,000.00. Following the completion of the sale, the executive vice president now directly owns 31,517 shares in the company, valued at approximately $1,040,061. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ DRNA opened at $33.56 on Friday. The firm’s 50-day moving average is $28.99. Dicerna Pharmaceuticals, Inc. has a 1-year low of $16.50 and a 1-year high of $33.78. The firm has a market capitalization of $2.58 billion, a price-to-earnings ratio of -20.98 and a beta of 1.10.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.11). Dicerna Pharmaceuticals had a negative net margin of 67.58% and a negative return on equity of 82.91%. The company had revenue of $47.60 million for the quarter, compared to analyst estimates of $59.56 million. On average, equities research analysts anticipate that Dicerna Pharmaceuticals, Inc. will post -0.7 earnings per share for the current year.
A number of analysts have commented on DRNA shares. Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 5th. Chardan Capital upped their price target on shares of Dicerna Pharmaceuticals from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Tuesday, March 2nd. B. Riley upped their price target on shares of Dicerna Pharmaceuticals from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, March 1st. The Goldman Sachs Group started coverage on shares of Dicerna Pharmaceuticals in a research report on Friday, April 16th. They set a “buy” rating and a $48.00 price target on the stock. Finally, Truist upped their price target on shares of Dicerna Pharmaceuticals from $35.00 to $45.00 in a research report on Monday, April 19th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Dicerna Pharmaceuticals presently has an average rating of “Buy” and an average target price of $42.29.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain.
Featured Story: Asset Allocation
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.